Cover Story
Vitrakvi (larotrectinib) aims to treat a very small group of people—some say fewer than 3,000 new patients a year in the U.S. And since these patients have diseases that span multiple tumor sites, finding them isn't easy.
In Brief
Clinical Roundup
Drugs & Targets
Trending Stories
- In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch
- Pooled analysis questions reliability of an endpoint used in multi-cancer detection trials
- My bad: I left out Fox Chase
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- NCI creates Cancer Equity Leaders group to improve cancer health equity
- Edward Copeland, surgeon and breast cancer expert, dies at 86